Phase 1b data in the first 50% of patients reflect the responses seen in animals and may suggest superiority in both safety and efficacy when compared to oral Revlimid®Anticipate FDA alignment and...
PARAMUS, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., (Starton or the Company), a clinical-stage biotechnology company focused on transforming standard-of-care therapies...
PARAMUS, N.J., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (œStarton or the œCompany), a clinical-stage biotechnology company focused on transforming standard-of-care therapies...
Regional Medical Oncology Center is activated and open to screen patientsStudy enrollment is ahead of schedule with half of the patients enrolled and complete enrollment which was previously...
STARTICLES, referring to proprietary and novel solid-state particulates suspended within a drug-in-adhesive patch for delivery of active pharmaceutical ingredients (API) developed by Starton...
Study enrollment is ahead of schedule with half of the patients enrolled and complete enrollment is expected by Q3/24Early data may suggest superiority in safety compared to oral Revlimid No...
Novel platform technology potentially expands the number of active pharmaceutical ingredients that can be delivered transdermallyTechnology offers a unique approach to maintaining concentration...
PARAMUS, N.J., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc., (the Company) a clinical-stage biotechnology company focused on transforming standard-of-care therapies with proprietary...
Two patients have been dosed and a third is in screeningThe first patient has completed cycle 1 successfully where he obtained a measurable response with a decrease in M-protein from 1.7 to 0.9 gm/dL...
Starton Therapeutics Announces Termination of Business Combination Agreement with Healthwell Acquisition Corp. I